DOYLESTOWN, PA--(MARKET WIRE)--Jun 28, 2007 -- QuantRx® Biomedical Corporation (OTC BB:QTXB.OB - News), an emerging leader in the research and development of medical diagnostic platforms and products, today announced that FluoroPharma, a QuantRx affiliate, completed 12 healthy volunteers in a Phase I clinical trial for CardioPET. The Phase I trial is a single center, open label study, designed to evaluate safety, distribution, and dosimetry of CardioPET as a PET tracer for myocardial imaging in healthy subjects. The study was led by Dr. Alan Fischman, Director of the Nuclear Medicine Division at Massachusetts General Hospital. CardioPET™ was exceedingly well tolerated, with no adverse events or clinically significant laboratory findings observed. Total radiation exposure was minimal and well within safety limits. Based on these results, IRB approved the initiation of CardioPET™ in a small group of stable CAD patients.
